W2T.Life Ltd
cropped-logosmall.png

W2T LIFE



About Us

We are a fast growing seed stage specialty pharmaceutical start up with the following values:
Clear focus

A specialty pharmaceutical company focused on formulated niche products with new indications.

Experienced LEADERSHIP

Many years successful experience building and growing companies; extensive clinical and scientific capabilities, proven track-record of product launches worldwide.

sCALABLE wORLDWIDE pLATFORM

Scalable platform established through initial portfolio of products.

Strong network to develop pipeline through license/acquisitions with minimal incremental costs

UK HQ & Irish subsidiary for EU licensing

ATTRACTIVE LEAD Opportunity

Lead product has a clear competitive advantage to compete in the $2bn* global market opportunity. 

Significantly de-risked by using 100% ‘natural’ active ingredients that cannot be manufactured, attractive market position, cheap to produce, medical device in EU.

Further Value Creation

Opportunity to develop additional assets to treat at least 13 conditions highly prevalent across the life course of all women (irrespective of age, background or ethnicity), for which no treatments exist or are inadequate  whilst securing new indications for existing products.

Investment

Management owned company seeking to raise £3 x 10M to develop the portfolio through to commercialisation for the 3 distinct projects and  extend licenses into Europe

Meet Our Experienced Board of Directors

Naushed Careem
naushed careem
Corporate Affairs

Experience/Expertise
-Social Entrepreneur and Campaigner

Companies/Trade Bodies
-Founder of the Blue Sky Network (anti-hate/social justice);
-The Blue Sky Village (end global poverty)

Previous Product Launch Examples
-Global Tribute to Nelson Mandela 
-Anne Frank Decalaration on Human RIghts

Shafiq Choudhary-copu
shafiq choudhary
Chief Operating Officer

Experience/Expertise
-Pharma / Life Sciences
-Sales & Marketing
-European markets
-Growth / M&A Market Access
-Investments

Companies/Trade Bodies
-Pfizer;
-Wyeth;
-Janssen;
-Archimedes Pharma;
-Co-Founder Intrapharm Laboratories (acquired by Riemser);
-Founded Tetris Pharma (acquired by Arecor Therapeutics)

Previous Product Launch Examples
-Ogluo®

Paul Long copy
Paul Long
Pharma Solutions

Experience/Expertise
-35+ years Life Sciences / Pharma
-International
-Personal care product roll out across worldwide markets
-Tech transfers
-Regulatory, governance

Companies/Trade Bodies
-Glaxo Group Research Ltd;
-Terragen Inc;
-SemGen DOO;
-Aethic Ltd.

Previous Product Launch Examples
-Dermagie® (Skin antiaging)

Jude Oben-copy
Jude Oben
Chief Executive Officer

Experience/Expertise
-Consultant Clinician- Scientist: MD, PhD, FRCP, AGAF Gastroenterologist & Hepatologist
-Director of Research at 1 Alpha-1 Ltd Director of Medical Education at ICU Ltd 
Over 15years Experience of Medical Financing

Companies/Trade Bodies
-Hoechst Ltd
–Sanofi
-Aventis;
-CellTech Pharmaceuticals;
-Cycle Pharmaceuticals.
Over 18+ years of experience in clinical studies in obesity, liver disease and diabetes-induced liver disease.

Previous Product Launch Examples
-Anti-Tumour Necrosis Factor (Infliximab).

Alastair Sutcliffe - Copy
Alastair Sutcliffe
Consultant Physician

Experience/Expertise
-Consultant Clinician Scientist: MD, PhD FRCP FRCPCH
-Paediatrician
-Chief Medical Officer FreddieMed.Com
30 years plus experience in research in diseases of early life (conception, pregnancy newborns)

Companies/Trade Bodies
-Zogenix Inc DSMB member
-CMO Guts N Gizzards Ltd
-Medical advisor V&Me
-Qualified Clinical Trialist

Previous Product Launch Examples
-Fintepla ( fenfluramine)

cropped-cropped-logosmall.png
TWO Investor nominated neds

We are expanding our team with Two investor nominated NEDs!

Skill Set Requirements:
-Sales & Marketing
-Business development
-Product Innovation

-Public market experience
-Corporate governance
-Financial expertise

Committees:

 -Audit & Risk
-Remuneration

Contact us if interested!

WHAT MAKES US SPECIAL

A EUROPEAN PLATFORM DRIVING GROWTH THROUGH SELECTIVE PENETRATION IN;
  • $2B PERSONAL CARE FOR WOMEN MARKET – through Mia Medicina
  • Diabetic Liver Disease
  • Skin
Learn core built expertise

- Established complementary expertise across medical & pharmaceutical management 

- Extensive product rollout experience across Europe and the UK 

- Leveraging networks, key opinion leads and relationships to fast-track product sales 

- Applying reimbursement knowledge to maximise opportunity

expand reach through asset-light model

- Senior management includes core competencies overseeing regulation, sales and marketing, supply chain, quality & finance 

- Outsourcing labour-intensive functions 

- Prebiotics over-the counter (OTC) – allows building flexible commercial capability through dedicated contract sales organisations and web-channel approach 

- Leveraging specialist expertise in non-core functions

drive revenue and margins with 
bolt-on generic+pipeline

 - Targeting European, North American & Asian markets 

- Additional ‘internal’ assets will leverage efficiencies from platform 

- Active pipeline enhanced through extensive network of worldwide  research contacts.

- Leadership team incentivised through equity Ongoing conversations with Enterprise Ireland to enter the EU market

exploiting scarcity of versatile pan european partners


- Seeking to become the pan European partner of choice for commercializing evidence-based microbiome-based products 

- Commercially opportunistic, therapeutically agnostic and flexible

*Market opportunity sources:

https://www.delveinsight.com/report-store/bacterial-vaginosis-market https://neighborwebsj.com/uncategorized/4046193/bacterial-vaginosis-drug-market-forecast-analysis- 2021-2024-growth-by-forthcoming-developments-future-prospects-opportunity-industry-scope-business- strategy-and-covid-19-market-scenario-report/

https://www.grandviewresearch.com/industry-analysis/vaginitis-therapeutics-market

https://www.globenewswire.com/news-release/2020/12/21/2148395/0/en/Women-s-Health-Market- to-Touch-USD-41-05-Billion-at-3-2-CAGR-by-2027-Growing-Focus-on-Women-s-Health-Worldwide-to- Positively-Impact-the-Market-Fortune-Business-Insights.html